Skip to main content
HOSPITALScience City Rd+91 97234 31544
AEC CLINICNaranpura+91 70460 02566
WhatsApp Hospital 11:00 AM – 8:00 PM | Clinic 8:30 AM – 10:30 AM

Balaji Horizon Women's Hospital

Last clinically reviewed by Dr. Priyadatt Patel on 10 June 2026

IVF · When IVF cycles do not succeed

Recurrent implantation failure — a structured approach when good embryos do not implant

Recurrent implantation failure (RIF) is the term used when multiple good-quality embryos fail to result in clinical pregnancy. The definition is not universally agreed, the causes are partly understood, and many of the proposed therapies have weak evidence behind them. This page describes a structured approach — what to investigate, what to treat, and what to avoid being over-tested for.

How RIF is defined

There is no single universally accepted definition. A practical working definition is the failure to achieve clinical pregnancy after the transfer of at least 4 good-quality embryos (cleavage or blastocyst) across a minimum of 3 fresh or frozen cycles in a woman under 40. Definitions vary; the principle is consistent — repeated failure despite morphologically good embryos and an apparently receptive endometrium.

Why definitions matter

Loose definitions of RIF lead to over-testing and over-treatment in patients who have simply had statistically expected outcomes. Many couples described as “RIF” after one or two failed transfers do not meet a meaningful clinical threshold. A structured work-up is reserved for true RIF, not for normal statistical variation.

Possible causes

  • Embryo-related — chromosomal aneuploidy (the largest single cause), morphologically good but biologically poor embryos
  • Endometrial — thin endometrium, polyps, fibroids distorting the cavity, adhesions, chronic endometritis
  • Adenomyosis — an under-diagnosed cause
  • Hydrosalpinx — tubal fluid that compromises implantation
  • Endometriosis — particularly deep or extensive disease
  • Thrombophilia — selected role; not all RIF patients need full thrombophilia screens
  • Immune dysfunction — controversial and over-investigated in many clinics
  • Lifestyle factors — BMI extremes, smoking, alcohol, untreated thyroid disease, vitamin deficiency

The structured work-up

  1. History review — prior cycles, embryo quality, embryo transfers, fertilisation methods, ovarian response, sperm parameters across cycles
  2. Saline-infusion sonohysterography or hysteroscopy — to exclude intrauterine pathology (polyps, fibroids, adhesions, septum)
  3. Endometrial biopsy with chronic endometritis screen — CD138 immunohistochemistry; treatable cause if positive
  4. MRI or detailed ultrasound — for adenomyosis and deep endometriosis
  5. Karyotype of both partners — balanced translocations
  6. Tubal evaluation — hydrosalpinx detection
  7. Targeted thrombophilia screen — antiphospholipid antibodies; broader thrombophilia testing only in selected cases
  8. Thyroid and prolactin
  9. Vitamin D, ferritin, HbA1c where indicated
  10. Sperm DNA fragmentation — selectively, particularly with male-factor history

Interventions with reasonable evidence

  • Hysteroscopic removal of polyps, submucous fibroids, septae, adhesions
  • Antibiotics for chronic endometritis — doxycycline or targeted antibiotic per culture
  • Salpingectomy or proximal occlusion for hydrosalpinx before next transfer
  • Optimisation of adenomyosis — GnRH agonist pre-treatment in selected cases
  • PGT-A — in selected RIF cases, particularly with advanced maternal age
  • Lifestyle correction — BMI, smoking, alcohol, thyroid status
  • Low-dose aspirin and LMWH — selected use where antiphospholipid syndrome is established

Interventions with weak or no evidence

Several “RIF treatments” are widely advertised but have poor evidence:

  • Intravenous immunoglobulin (IVIG) — not recommended outside research
  • Intralipid infusion — not supported by good evidence
  • Granulocyte colony-stimulating factor (G-CSF) — selected use; evidence mixed
  • Endometrial scratching — evidence does not support routine use
  • NK cell testing and immunomodulation — current consensus is that uterine NK testing is not clinically actionable
  • Heparin in the absence of thrombophilia — not supported
  • Embryo glue, embryo growth media additives — small to no clinical benefit
  • ERA (endometrial receptivity array) — not supported as a routine investigation by current evidence

Patients are explicitly told what the evidence does and does not support, and offered the choice transparently.

When to consider alternatives

  • Persistent failure despite full structured work-up and corrected modifiable factors
  • Embryo quality limitations (advanced maternal age, declining reserve)
  • Patient and couple values around continuing with own gametes or considering donor pathways
  • The option to pause cycles and re-evaluate with fresh eyes

The institutional approach

This centre approaches RIF as a structured diagnostic problem rather than as a marketing opportunity. The work-up follows the evidence. Interventions with weak evidence are not pushed. Patients are told the truth about what is known and what is still uncertain. Where the underlying issue is embryo quality and time has run, the conversation about alternatives is opened gently and without pressure.

When to seek a second opinion

  • After two or three failed transfers without a structured work-up
  • If multiple add-ons are being recommended without evidence discussion
  • If hysteroscopy or endometritis screen has not been done despite multiple failures
  • If a clinic has not addressed hydrosalpinx, adenomyosis, or chronic endometritis as part of the plan

Guidelines we follow on this topic

  • ESHRE Good Practice Recommendations on Repeated Implantation Failure
  • ASRM committee opinion on RIF
  • RCOG guidance on recurrent miscarriage and implantation failure
  • Cochrane reviews on RIF interventions

RIF requires a structured workup: endometrial assessment, uterine cavity evaluation, embryo quality, immunological factors where indicated, and male factor re-assessment. Empirical treatments without evidence base should be avoided.

— ESHRE Recurrent Implantation Failure Guideline, 2023

CONTINUE READING

Recurrent implantation failure — what we assess

DomainAssessed
EmbryoGenetic testing (PGT)
UterusCavity and lining
SystemicThyroid, metabolic, selected immune/clotting
TechniqueThe transfer

Explore the IVF Programme

Recurrent Implantation Failure is one part of the broader IVF and fertility programme. The main IVF pillar covers individualised protocols, success counselling, and long-term reproductive planning.

Free Patient Guide

The IVF Readiness Checklist

A clinically grounded primer covering AMH ranges, the cycle in plain terms, ten questions to ask, and honest international live-birth reference data by age band.

Reviewed by Dr. Priyadatt Patel — read in 20–25 minutes

Get the guide →

Free — delivered to your inbox

Your fertility team
Dr Priyadatt Patel, fertility and reproductive surgeon, Ahmedabad

Dr Priyadatt Patel
Lead — Fertility, Endometriosis & Reproductive Surgery

Dr Patel leads fertility care at Balaji Horizon, integrating reproductive surgery and IVF into a single plan — ethical, evidence-based and individualised, with realistic expectations and no overpromising of success.

Dr Shreya Iyengar Patel, fertility and reproductive medicine, Ahmedabad

Dr Shreya Iyengar Patel
Fertility & Reproductive Medicine
Talk to our fertility team

Individualised IVF and fertility planning with honest, evidence-based counselling — and realistic expectations from the very first consultation.

Book a consultation

Frequently asked questions

How many failed transfers define recurrent implantation failure?
A practical threshold is failure to achieve clinical pregnancy after transfer of at least 3 good-quality cleavage-stage embryos, or 2 good-quality blastocysts, in a woman under 40 with normal uterine anatomy. Definitions vary; the principle is repeated failure despite morphologically good embryos.
What causes recurrent implantation failure?
Embryo factors (often aneuploidy), uterine receptivity issues, chronic endometritis, anatomic factors, selected immune and thrombotic factors, and sperm DNA fragmentation. Several factors often combine, and many cases remain unexplained after a thorough work-up.
Should I have PGT-A after recurrent implantation failure?
Often considered, particularly in patients over 35 or with multiple unexplained failures, as it can identify aneuploidy as the cause. It is a selective, individualised decision rather than a routine add-on.
What is the ERA (endometrial receptivity array) test?
A molecular test proposed to identify the optimal window of implantation. Current evidence does not support it as a routine investigation; it is used selectively, if at all, after the standard structured work-up.
Is chronic endometritis common in RIF?
It is found in roughly 15-30% of RIF cases, is often asymptomatic, and is diagnosed by CD138 plasma-cell staining on endometrial biopsy. It is treatable with targeted antibiotics and should be excluded as part of the work-up.
Do immune therapies help recurrent implantation failure?
Evidence is weak for most immunomodulators (IVIG, intralipid, G-CSF). They are reserved for specific, confirmed indications such as antiphospholipid syndrome; empirical use without a clear indication is not supported.
What is endometrial scratching, and does it work?
Deliberate minor endometrial injury before a transfer cycle, once hypothesised to improve receptivity. The evidence has weakened over time and does not support routine use.
Should both partners be reinvestigated for RIF?
Yes. Sperm DNA fragmentation testing is valuable because the male contribution is often underestimated in RIF, and lifestyle optimisation of the male partner can improve outcomes.

★★★★★5.0 · 282 Verified Google Reviews

Dr. Priyadatt Patel

Senior Gynecologist · Advanced Laparoscopic Surgeon · IVF and Endometriosis Programme Lead

MS OBGyn · Pregnancy Care · Advanced Gynaecological Ultrasound · Fertility Preservation

ESHRE / ESGE / AAGL / ASRM guideline-aligned practice. 3D Karl Storz precision technique. Fertility-preservation-first philosophy. Evidence-based decisions, honest counselling, long-term outcomes orientation.

Endometriosis
Superficial to deep infiltrating, fertility-preserving excision
IVF & Fertility
Individualised protocols, ART Level 2 lab, transparent outcomes
Advanced Laparoscopy
3D Karl Storz precision, nerve-sparing technique
Pregnancy Care
Antenatal care, high-risk pregnancy, advanced ultrasound
Balaji Horizon Women Hospital
Science City Road, Ahmedabad 380060
Mon–Sat 11:00–20:00 · +91 97234 31544
Balaji Women Clinic (AEC)
Naranpura, Ahmedabad
Mon–Sat 08:30–10:30 · +91 70460 02566
Bureau Veritas ISO 9001 UKAS accreditation 0008 — Balaji Horizon Women's Hospital

Internationally Accredited · State Registered

ISO 9001:2015 Quality Management System — UKAS Accredited Certification by Bureau Veritas

Certificate IND.25.899/QM/U · Valid until 02 September 2028 · Independently verify at certcheck.ukas.com

Permanently registered under Gujarat Clinical Establishments Act, 2021 · Reg. No. CEA/AHD/262/2025 · Single Speciality Hospital · 15 Beds

Operated by Balaji Women’s Clinic · Trading as Balaji Horizon Women’s Hospital

CALL BOOK ON WHATSAPP